The Claim

E2HSA exhibits insulinotropic activity on rat pancreatic islets and GLP-1R-dependent biological activity in RIN-m5F cells in vitro, although with lower potency compared to exendin-4, indicating that it maintains functional biological activity despite structural modifications.

Source: A novel exendin-4 human serum albumin fusion protein, E2HSA, with an extended half-life and good glucoregulatory effect in healthy rhesus monkeys.

What the research says

Roughly balanced

Support and challenge are close. The picture may shift as more studies come in.

Supports
6score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

How it works
1 study reviewed
In plain English

A modified compound called E2HSA still works in lab tests like a diabetes drug, even if it's not as strong as the original version.

See the scientific wording

In vitro, E2HSA demonstrates insulinotropic activity on rat pancreatic islets and GLP-1R-dependent biological activity in RIN-m5F cells, though with lower potency than exendin-4, indicating it retains functional biological activity despite structural modification.

What the research says

1 study

  1. Study: A novel exendin-4 human serum albumin fusion protein, E2HSA, with an extended half-life and good glucoregulatory effect in healthy rhesus monkeys.

    The study tested E2HSA in lab-grown cells and found it works similarly to exendin-4, just a bit weaker, which matches what the claim says.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.